Source: Eur Respir J, 53 (3) 1802191; 10.1183/13993003.02191-2018
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Nina Cramer, Ludwig Sedlacek, Burkhard Tümmler, Tobias Welte. Low transmission risk of Pseudomonas aeruginosa in a bronchiectasis clinic based on the knowledge of bacterial population biology. Eur Respir J, 53 (3) 1802191; 10.1183/13993003.02191-2018

Member's Comments

No comment yet.

Related content which might interest you: The clinical impact of Pseudomonas aeruginosa eradication in bronchiectasis in a Dutch referral centre Source: Eur Respir J, 53 (4) 1802081; 10.1183/13993003.02081-2018 Year: 2019 Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with COPD. Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Cystic fibrosis infection with clonal strains of Pseudomonas aeruginosa: current knowledge and future management Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=105 Year: 2006 The clinical impact of pseudomonas aeruginosa eradication in bronchiectasis in a Dutch center of expertise Source: International Congress 2018 – Bronchiectasis: phenotypes, endotypes and new therapies Year: 2018 The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis Source: Eur Respir J, 51 (2) 1701953; 10.1183/13993003.01953-2017 Year: 2018 Does a single Pseudomonas aeruginosa isolation predict COPD mortality? Source: Eur Respir J 2014; 44: 794-797 Year: 2014 Risk factors and outcomes of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa: a clinical case-control study Source: International Congress 2017 – Respiratory infections in critically ill and immuno-depressed patientes Year: 2017 Identifying patients with pneumonia due to MDR organisms coming from the community Source: Eur Respir Monogr 2017; 75: 97-110 Year: 2017 Omics-based tracking of Pseudomonas aeruginosa persistence in “eradicated” cystic fibrosis patients Source: Eur Respir J, 57 (4) 2000512; 10.1183/13993003.00512-2020 Year: 2021 Can LCI predict new Pseudomonas aeruginosa colonization among CF patients?> Source: International Congress 2017 – What is the future for paediatric respiratory physiology and sleep? Year: 2017 Newly acquired pseudomonas aeruginosa in Belgian cystic fibrosis-patients: does the patients‘ P. aeruginosa genotype correlate with environmental genotypes? Source: Eur Respir J 2006; 28: Suppl. 50, 485s Year: 2006 Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Source: Eur Respir J 2006 Oct 01;28(4):740-747 Year: 2006 Molecular genetic characteristics of Pseudomonas aeruginosa strains isolated from children with cystic fibrosis in Moscow. Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects Year: 2021 A comprehensive analysis of the impact of pseudomonas aeruginosa colonisation in adult bronchiectasis Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 Predicting the outcome of respiratory Pseudomonas aeruginosa infection in vivo Source: International Congress 2017 – Cystic fibrosis: treatments and monitoring Year: 2017 DNA fingerprinting of Pseudomonas aeruginosa (Pa) in cystic fibrosis patients: risk assessment of cross-colonisation in a CF revalidation centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002 DNA fingerprinting of pseudomonas aeruginosa in cystic fibrosis patients: risk assessment of cross-infection in a CF centre Source: Eur Respir J 2002; 20: Suppl. 38, 208s Year: 2002 Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Source: Eur Respir J 2008; 31: 822-829 Year: 2008